U-EXCEL

Inclusion Criteria:

- Confirmed diagnosis of CD for at least 3 months prior to Baseline.

- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),
abdominal pain (AP) score.

- Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's
disease (SES-CD) on an endoscopy confirmed by a central reader.

- Demonstrated an inadequate response or intolerance to one or more conventional and/or
biologic therapies (oral locally acting steroids, intravenous or oral corticosteroids,
immunosuppressants or biologic therapies for CD), in the opinion of the investigator.

- Note: Participants who have had inadequate response or intolerance to
conventional therapy who have received prior biologic may be enrolled; however,
participants must have discontinued the biologic for reasons other than
inadequate response or intolerance (e.g., change of insurance, well controlled
disease).

- If female, participant must meet the contraception recommendations.

Exclusion Criteria:

- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.

- Participant not on stable doses of CD related antibiotics, oral aminosalicylates,
corticosteroids or methotrexate (MTX).

- Participant with the following ongoing known complications of CD: abscess (abdominal
or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, > 2
entire missing segments of the following 5 segments: terminal ileum, right colon,
transverse colon, sigmoid and left colon, and rectum, or any other manifestation that
might require surgery while enrolled in the study.

- Participant with ostomy or ileoanal pouch.

- Participant diagnosed with conditions that could interfere with drug absorption
including but not limited to short gut or short bowel syndrome.

- Screening laboratory and other analyses show abnormal results.